Video

It's an Exciting Time for Myelodysplastic Syndrome

Learning more about MDS will lead to better diagnostics and more personalized treatments.

It’s an exciting time in the field of myelodysplastic syndrome (MDS), explained Amy DeZern, M.D., associate professor of Oncology and Medicine at the Johns Hopkins University School of Medicine.

Researchers and practitioners alike are learning more about the biology of the disease, as well as the molecular mutations that come along with it. This is helping to differentiate different subtypes of MDS — it is not a heterogenous disease – which will lead to better diagnostic and prognostic accuracy, as well as paving the way for the use of targeted therapy in this space.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
Image of valarie with text.
Image of Dr. with text.
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.